Generic Name and Formulations:
Interferon alfa-2b, recombinant; 10million IU, 18million IU, 25million IU; per vial; for inj; contains m-cresol.
Company:
Merck & Co., Inc.
AIDS-related Kaposi's sarcoma.
Use appropriate preparation and route: see literature. Use SC route if platelets <50,000/mm3. 30million IU/m2 IM or SC three times weekly; continue until rapid disease progression or maximal response achieved after 16 wks; reduce dose by ½ or suspend therapy if severe adverse reactions occur; discontinue if persists.
Not recommended.
Hepatitis: decompensated liver disease. Autoimmune disorders.
May cause or exacerbate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, or infectious disorders: monitor closely, discontinue if they worsen. Severe psychiatric disorders (esp. depression). Cardiovascular or pulmonary disease. Severe myelosuppression. Uncontrolled thyroid abnormalities. Diabetes. Coagulation disorders. Maintain adequate hydration. Monitor blood, thyroid, visual and liver function before and during therapy; EKG in cardiovascular disease and cancer patients. Psoriasis. Renal dysfunction. Transplant recipients. Elderly. Debilitated. Pregnancy (Cat.C). Nursing mothers: not recommended.
Caution with myelosuppressives, and drugs that can exacerbate depression. May potentiate theophylline (may double its levels).
Flu-like symptoms (fever, headache, myalgia, fatigue); hepatic, hematologic, respiratory, skin, genitourinary system, CNS, cardiovascular, endocrine (esp thyroid), GI, or visual disorders; colitis, hypertriglyceridemia, pancreatitis, infections, injection site reactions; others (see literature).
Pwd (w. diluent): 10million, 18million, 50million IU/vial—1; Soln (vials): 10million IU/vial—6 (kit w. supplies); Soln (multidose vials): 18million, 25million IU/vial—1; Soln (multidose pens, 6 doses/pen): 3million IU/0.2mL, 5million IU/0.2mL, 10million IU/0.2mL—1
Hairy cell leukemia. Initial treatment of clinically aggressive follicular Non-Hodgkin's lymphoma in conjunction with anthracycline-containing combination chemotherapy.
Use SC route if platelets <50,000/mm3. Hairy cell leukemia: 2million IU/m2 IM or SC 3 times a week for up to 6 months. Follicular lymphoma: 5million IU SC 3 times a week for up to 18 months in conjunction with anthracycline-containing chemotherapy regimen and following completion of the chemotherapy regimen. See literature for appropriate preparation and route and for dose adjustments.
Not recommended.
Hepatitis: decompensated liver disease. Autoimmune disorders.
May cause or exacerbate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, or infectious disorders: monitor closely, discontinue if they worsen. Severe psychiatric disorders (esp. depression). Cardiovascular or pulmonary disease. Severe myelosuppression. Uncontrolled thyroid abnormalities. Diabetes. Coagulation disorders. Maintain adequate hydration. Monitor blood, thyroid, visual and liver function before and during therapy; EKG in cardiovascular disease and cancer patients. Psoriasis. Renal dysfunction. Transplant recipients. Elderly. Debilitated. Pregnancy (Cat.C). Nursing mothers: not recommended.
Caution with myelosuppressives, and drugs that can exacerbate depression. May potentiate theophylline (may double its levels).
Flu-like symptoms (fever, headache, myalgia, fatigue); hepatic, hematologic, respiratory, skin, genitourinary system, CNS, cardiovascular, endocrine (esp thyroid), GI, or visual disorders; colitis, hypertriglyceridemia, pancreatitis, infections, injection site reactions; others (see literature).
Pwd (w. diluent): 10million, 18million, 50million IU/vial—1; Soln (vials): 10million IU/vial—6 (kit w. supplies); Soln (multidose vials): 18million, 25million IU/vial—1; Soln (multidose pens, 6 doses/pen): 3million IU/0.2mL, 5million IU/0.2mL, 10million IU/0.2mL—1
Malignant melanoma.
Induction: 20million IU/m2 IV over 20 minutes, 5 consecutive days per week, for 4 weeks. Maintenance: 10million IU/m2 SC 3 times per week for 48 weeks. See literature for appropriate preparation and route and for dose adjustments.
Not recommended.
Hepatitis: decompensated liver disease. Autoimmune disorders.
May cause or exacerbate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, or infectious disorders: monitor closely, discontinue if they worsen. Severe psychiatric disorders (esp. depression). Cardiovascular or pulmonary disease. Severe myelosuppression. Uncontrolled thyroid abnormalities. Diabetes. Coagulation disorders. Maintain adequate hydration. Monitor blood, thyroid, visual and liver function before and during therapy; EKG in cardiovascular disease and cancer patients. Psoriasis. Renal dysfunction. Transplant recipients. Elderly. Debilitated. Pregnancy (Cat.C). Nursing mothers: not recommended.
Caution with myelosuppressives, and drugs that can exacerbate depression. May potentiate theophylline (may double its levels).
Flu-like symptoms (fever, headache, myalgia, fatigue); hepatic, hematologic, respiratory, skin, genitourinary system, CNS, cardiovascular, endocrine (esp thyroid), GI, or visual disorders; colitis, hypertriglyceridemia, pancreatitis, infections, injection site reactions; others (see literature).
Pwd (w. diluent): 10million, 18million, 50million IU/vial—1; Soln (vials): 10million IU/vial—6 (kit w. supplies); Soln (multidose vials): 18million, 25million IU/vial—1; Soln (multidose pens, 6 doses/pen): 3million IU/0.2mL, 5million IU/0.2mL, 10million IU/0.2mL—1
Genital warts.
Use appropriate preparation and route: see literature. Use SC route if platelets <50,000/mm3. Inject intralesionally 1million IU/lesion 3 times weekly on alternate days for 3 wks; treat up to 5 lesions at one time. May repeat treatment as above after 12–16 wks.
Not recommended.
Hepatitis: decompensated liver disease. Autoimmune disorders.
May cause or exacerbate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, or infectious disorders: monitor closely, discontinue if they worsen. Severe psychiatric disorders (esp. depression). Cardiovascular or pulmonary disease. Severe myelosuppression. Uncontrolled thyroid abnormalities. Diabetes. Coagulation disorders. Maintain adequate hydration. Monitor blood, thyroid, visual and liver function before and during therapy; EKG in cardiovascular disease and cancer patients. Psoriasis. Renal dysfunction. Transplant recipients. Elderly. Debilitated. Pregnancy (Cat.C). Nursing mothers: not recommended.
Caution with myelosuppressives, and drugs that can exacerbate depression. May potentiate theophylline (may double its levels).
Flu-like symptoms (fever, headache, myalgia, fatigue); hepatic, hematologic, respiratory, skin, genitourinary system, CNS, cardiovascular, endocrine (esp thyroid), GI, or visual disorders; colitis, hypertriglyceridemia, pancreatitis, infections, injection site reactions; others (see literature).
Pwd (w. diluent): 10million, 18million, 50million IU/vial—1; Soln (vials): 10million IU/vial—6 (kit w. supplies); Soln (multidose vials): 18million, 25million IU/vial—1; Soln (multidose pens, 6 doses/pen): 3million IU/0.2mL, 5million IU/0.2mL, 10million IU/0.2mL—1